Despite facing regulatory issues with the generic business, JUBILANT to report at least 10% revenue growth in our view, aided by increasing traction in specialty segments and LSI business. However, margin expansion at 150bps (FY19-21E) is likely to be slower than anticipated earlier due to persistent cost pressures in LSI and inferior business mix. Still, with the help of reduced debt (by US$ 135mn), we expect EPS to deliver 19% CAGR over FY19-21E. With a 30% fall in stock price over the last 2 months owing to regulatory issues, the valuations have become really attractive at 10/8x FY20/21E P/E. Maintain BUY We maintain BUY on JUBILANT despite a miss on our estimates. Our TP is revised at Rs 915/sh (12x FY21E EPS) following a 9% cut in FY21E EPS due to inferior biz mix.